Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has initiated a new Phase 3 trial to investigate the efficacy and safety of Epidiolex (cannabidiol), known as Epidyolex in Europe, in children and adolescents with e
Trial is the first randomized, controlled clinical trial evaluating cannabidiol to treat children and adolescents living with a developmental and epileptic encephalopathy known as Epilepsy with